Optasia Medical’s premier product, SpineAnalyzer, is a workflow tool for the quantitative assessment of vertebral deformities in patients at risk of osteoporotic fractures.

The output of the device may be used by physicians to assist in the diagnosis of vertebral fractures, a key factor to determine if therapeutic intervention is indicated.

Optasia Medical Business Development VP for the US Jim DePass said the company is very pleased to have joined twenty-two other leading healthcare organizations and providers in support of the initiatives of the NBHA.

"Despite the availability of bone densitometry and pharmacological therapies, the incidence and costs related to osteoporosis have not decreased. What we sorely need to reduce these costs is more public awareness of osteoporosis in combination with better tools for diagnosis and treatment and that is the goal of the NBHA," DePass said.

NBHA’s founding members include the American Academy of Orthopedic Surgeons, American Society for Bone and Mineral Research, Health Monitor Network, National Osteoporosis Foundation, the Paget Foundation for Paget’s Disease of Bone and Related Disorders and the Osteogenesis Imperfecta Foundation.